Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Ptc Therapeutics (PTCT) Cash & Current Investments: 2011-2024

Historic Cash & Current Investments for Ptc Therapeutics (PTCT) over the last 14 years, with Dec 2024 value amounting to $1.1 billion.

  • Ptc Therapeutics' Cash & Current Investments rose 66.56% to $1.7 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $6.8 billion, marking a year-over-year increase of 76.93%. This contributed to the annual value of $1.1 billion for FY2024, which is 29.99% up from last year.
  • As of FY2024, Ptc Therapeutics' Cash & Current Investments stood at $1.1 billion, which was up 29.99% from $876.7 million recorded in FY2023.
  • Ptc Therapeutics' Cash & Current Investments' 5-year high stood at $1.1 billion during FY2024, with a 5-year trough of $410.7 million in FY2022.
  • Moreover, its 3-year median value for Cash & Current Investments was $876.7 million (2023), whereas its average is $809.0 million.
  • Its Cash & Current Investments has fluctuated over the past 5 years, first slumped by 46.89% in 2022, then surged by 113.47% in 2023.
  • Ptc Therapeutics' Cash & Current Investments (Yearly) stood at $1.1 billion in 2020, then decreased by 29.93% to $773.4 million in 2021, then tumbled by 46.89% to $410.7 million in 2022, then surged by 113.47% to $876.7 million in 2023, then rose by 29.99% to $1.1 billion in 2024.